CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Candel Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.21+0.02 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $608.62M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.88 (+54.03%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $608.62M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.83
- Dividend yield
- –
- Free cash flow yield
- -9.42%
Fundamentals
- Net income
- -$88.53M
- EPS, diluted
- -$1.41
- Free cash flow
- -$57.32M
- Book value per share
- $1.70
- Diluted shares
- 74M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$71.99M
Net income
-$88.53M
EPS, diluted
-$1.41
Free cash flow
-$57.32M
Reported periodTrailing twelve months